At a glance
ClinicalIndex Comparison RecordPhase 3Completed
Drug / intervention
Aridol +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Multicenter Study to Demonstrate the Sensitivity and Specificity of Aridol (Mannitol) Challenge to Predict Bronchial Hyperresponsiveness as Manifested by a Positive Exercise Challenge in Subjects Presenting With Signs and Symptoms Suggestive of Asthma But Without a Definitive Diagnosis
In Brief
A Phase 3 clinical trial evaluating Aridol, Methacholine, and 1 other intervention for Asthma. Completed, across 1 site.
Detailed Summary
This is a Phase 3 study to determine the sensitivity and specificity of the Aridol bronchial challenge test to detect bronchial hyperresponsiveness in patients with suspected asthma. Patients with suspected asthma of either gender, aged between 6 and 50 years, with only mildly impaired lung function (FEV1 \>70%) are to be tested with three different bronchial hyperresponsiveness challenges (Aridol, exercise and methacholine), and the results compared. A clinical diagnosis will also be made at the end of the study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2005
First PostedNov 2005
Study CompletionSep 2006
TodayJul 2026
First PostedNov 11, 2005
Enrollment StartNov 1, 2005
Study CompletionSep 1, 2006
TodayJul 2, 2026
Posted 20.6 years ago
Interventions
Aridoldrug
Methacholinedrug
Exercise challengeprocedure